WO2012027794A3 - Method of treatment and agents useful for same - Google Patents

Method of treatment and agents useful for same Download PDF

Info

Publication number
WO2012027794A3
WO2012027794A3 PCT/AU2011/001132 AU2011001132W WO2012027794A3 WO 2012027794 A3 WO2012027794 A3 WO 2012027794A3 AU 2011001132 W AU2011001132 W AU 2011001132W WO 2012027794 A3 WO2012027794 A3 WO 2012027794A3
Authority
WO
WIPO (PCT)
Prior art keywords
precursor protein
amyloid precursor
treatment
same
agents useful
Prior art date
Application number
PCT/AU2011/001132
Other languages
French (fr)
Other versions
WO2012027794A2 (en
Inventor
James Alexander Duce
Ashley Ian Bush
Original Assignee
The Mental Health Research Institute Of Victoria
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2010903933A external-priority patent/AU2010903933A0/en
Application filed by The Mental Health Research Institute Of Victoria filed Critical The Mental Health Research Institute Of Victoria
Publication of WO2012027794A2 publication Critical patent/WO2012027794A2/en
Publication of WO2012027794A3 publication Critical patent/WO2012027794A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
    • A61K31/198—Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/04—Chelating agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Abstract

The present invention relates generally to a method of treating conditions characterised by aberrant amyloid precursor protein ferroxidase activity and agents useful for same. More particularly, the present invention relates to a method of treating conditions characterised by aberrant amyloid precursor protein ferroxidase activity by modulating amyloid precursor protein ferroxidase activity, in particular modulating the interaction of zinc or GFD with amyloid precursor protein. The method of the present invention is useful, inter alia, in the treatment and/or prophylaxis of conditions including, but not limited to, Alzheimer's disease.
PCT/AU2011/001132 2010-09-01 2011-09-01 Method of treatment and agents useful for same WO2012027794A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AU2010903933A AU2010903933A0 (en) 2010-09-01 Method of treatment and agents useful for same
AU2010903933 2010-09-01

Publications (2)

Publication Number Publication Date
WO2012027794A2 WO2012027794A2 (en) 2012-03-08
WO2012027794A3 true WO2012027794A3 (en) 2012-04-26

Family

ID=45773303

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/AU2011/001132 WO2012027794A2 (en) 2010-09-01 2011-09-01 Method of treatment and agents useful for same

Country Status (1)

Country Link
WO (1) WO2012027794A2 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2614086T3 (en) 2005-04-04 2017-05-29 University Of Florida Research Foundation, Inc. Desferritiocin polyether analogs
JP5439193B2 (en) 2007-03-15 2014-03-12 ユニバーシティー オブ フロリダ リサーチ ファンデーション， インク． Desferrithiocin polyether analogue
WO2012142666A1 (en) * 2011-04-19 2012-10-26 The Mental Health Research Institute Of Victoria Method of modulating amine oxidase activity and agents useful for same
WO2013090750A1 (en) 2011-12-16 2013-06-20 University Of Florida Research Foundation, Inc. Uses of 4'-desferrithiocin analogs
AU2014352780A1 (en) 2013-11-22 2016-06-09 University Of Florida Research Foundation, Inc. Desferrithiocin analogs and uses thereof
WO2016100444A1 (en) * 2014-12-16 2016-06-23 University Of Florida Research Foundation, Inc. Treatment of closed head injury and hemorrhagic stroke with hbed
WO2016154682A1 (en) * 2015-04-02 2016-10-06 Crc For Mental Health Ltd Method for predicting risk of cognitive deterioration
AU2016255770A1 (en) 2015-04-27 2017-11-16 University Of Florida Research Foundation, Incorporated Metabolically programmed metal chelators and uses thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5705401A (en) * 1991-11-12 1998-01-06 The University Of Melbourne Method of assaying for alzheimer's disease
WO2003006044A1 (en) * 2001-07-12 2003-01-23 Novactyl, Inc. Methods and compositions for controlling protein assembly or aggregation
WO2005049026A1 (en) * 2003-11-19 2005-06-02 Acrux Dds Pty Ltd Method and composition for treatment or prophylaxis of amyloidosis disorders

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5705401A (en) * 1991-11-12 1998-01-06 The University Of Melbourne Method of assaying for alzheimer's disease
WO2003006044A1 (en) * 2001-07-12 2003-01-23 Novactyl, Inc. Methods and compositions for controlling protein assembly or aggregation
WO2005049026A1 (en) * 2003-11-19 2005-06-02 Acrux Dds Pty Ltd Method and composition for treatment or prophylaxis of amyloidosis disorders

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BUSH A. I.: "Drug Development Based on the Metals Hypothesis of Alzheimer's Disease", JOURNAL OF ALZHEIMER'S DISEASE, vol. 15, 2008, pages 223 - 240 *
FINEFROCK A. E. ET AL.: "Current Status of Metals as Therapeutic Targets in Alzheimer's Disease", JOURNAL OF THE AMERICAN GERIATRIC SOCIETY, vol. 51, no. 8, 2003, pages 1143 - 1148 *

Also Published As

Publication number Publication date
WO2012027794A2 (en) 2012-03-08

Similar Documents

Publication Publication Date Title
WO2012027794A3 (en) Method of treatment and agents useful for same
USD914887S1 (en) Wound dressing
EA201290041A1 (en) TREATMENT OF DISORDERS ASSOCIATED WITH MACROPHAGES
MX2012000034A (en) Methods for treating or preventing fatigue.
WO2012062925A3 (en) Compounds and methods for treating pain
WO2011073279A3 (en) Cosmetic treatment method involving a compound capable of condensing in situ
MX2009012163A (en) Hetarylanilines as modulators for amyloid beta.
MY160894A (en) Oligosaccharide composition for treating skin diseases
EA201490004A1 (en) BIFIDOBACTERIUM LACTIS BL-04 APPLICATION FOR TREATMENT OF RESPIRATORY DISEASES
MX2010007490A (en) Preparation of sulfamide derivatives.
WO2009089635A9 (en) Treating neurodegenerative diseases with progranulin (pgrn)
WO2012050831A3 (en) Combination treatment for dermatological conditions
WO2011140310A3 (en) Povidone-iodine topical composition
NZ601350A (en) Method of treating arthritis
WO2013098416A3 (en) Pain relief compounds
WO2010088450A3 (en) Arylamide derivatives useful in the treatment of diseases associated with serca activity
ATE538775T1 (en) KETOROLAC-TROMETHAMIN COMPOSITIONS FOR THE TREATMENT OR PREVENTION OF PAIN
WO2011089234A3 (en) Aqueous solution comprising 3 - quinuclidinones for the treatment hyperproliferative, autoimmune and heart disease
WO2012076109A3 (en) 2-pyrones
WO2009136997A3 (en) Inhibitors of human cathepsin l, cathepsin b, and cathepsin s
WO2012101156A3 (en) Human lactoferrin based peptides having antiinflammatory activity
WO2014145236A3 (en) The use of sdf-1 to mitigate scar formation
MX2014014066A (en) Chromane compounds.
WO2007103765A3 (en) Treatment with cyclosporin a
GB201216817D0 (en) Method of treatment or prevention of hair loss or for the enhancement of hair growth

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11820926

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11820926

Country of ref document: EP

Kind code of ref document: A2